Modular Medical, INC

Modular Medical, Inc. announced the pricing of a registered direct offering of 750,000 shares of common stock, raising approximately $3.4 million.

Modular Medical, Inc. has officially regained compliance with the Nasdaq minimum bid price requirement after maintaining a share price above $1.00 for 10 consecutive trading days.

Modular Medical, Inc. announced a 1-for-30 reverse stock split to maintain its Nasdaq listing, effective March 31, 2026.

Modular Medical, Inc. announced a significant workforce reduction impacting 29% of its employees to decrease operating expenses and cash burn.

Modular Medical, Inc. announced the successful pricing and closing of a $12 million public offering of common stock and warrants.

Modular Medical, Inc. has secured a $350,000 revolving credit facility from its CEO, James E. Besser, due March 25, 2026, at a 12% interest rate.

Modular Medical, a pre-revenue medical device company, reported increased operating losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Modular Medical, Inc. reported increased operating losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, while also facing Nasdaq delisting due to its stock price.

Modular Medical, Inc. announces its Q3 2025 results, emphasizing FDA clearance for its MODD1 insulin pump and ongoing efforts towards commercialization despite a going concern warning.

Modular Medical has filed an amendment to its quarterly report to correct an error regarding the electronic submission of interactive data files.

Modular Medical, a pre-revenue medical device company, announced its second quarter 2025 results, highlighting FDA clearance for its MODD1 insulin pump while reporting continued operating losses.

Modular Medical reported its Q1 2025 financial results, highlighting ongoing losses and raising concerns about the company's ability to continue as a going concern.

Modular Medical, Inc. announced FDA clearance for its Pivot insulin delivery system, marking a significant step towards commercialization and broader market adoption.

Modular Medical, Inc., a pre-revenue medical device company, has received FDA clearance for its MODD1 insulin pump and plans initial shipments by September 2025, while acknowledging substantial doubt about its ability to continue as a going concern without further capital.

Modular Medical's amended and restated 2017 Equity Incentive Plan aims to attract and retain top talent while promoting the company's success.

Philip Brent Sheibley, a Director at Modular Medical, Inc., acquired 250 stock options on June 30, 2026, under the company's Outside Director Compensation Plan.

Duane M. DeSisto, a Director at Modular Medical, Inc., acquired 83 shares of common stock on June 30, 2026, under the company's Outside Director Compensation Plan.

Director Frank Morgan C. acquired options to purchase 312 shares of Modular Medical, Inc. (MODD) under the company's Outside Director Compensation Plan.

Paul DiPerna, Chairman, President, and CFO of Modular Medical, was granted 11,218 stock options.

Modular Medical, Inc. Chief Operating Officer Kevin Schmid was granted 4,674 stock options as part of an equity incentive.

Director Frank Morgan C. reports acquisition of stock options in Modular Medical, Inc. (MODD) under the company's Outside Director Compensation Plan.

Modular Medical, Inc. will hold its fiscal 2026 Annual Meeting to address Nasdaq compliance, approve a reverse stock split, increase authorized shares, and amend its equity incentive plan amidst going concern doubts.

Modular Medical, Inc. is holding its 2025 Annual Meeting of Shareholders on February 28, 2025, to vote on key proposals including the election of seven directors, an increase in the company's equity incentive plan, and the ratification of its independent auditor.

Modular Medical, a pre-revenue medical device company, is conducting a best-efforts offering of up to $12 million in common stock and warrants to fund operations and commercialize its Pivot insulin pump, despite significant operating losses and going concern uncertainty.

A group of reporting persons, including Manchester Management Company, LLC and James E. Besser, filed an amended Schedule 13D to update their beneficial ownership in Modular Medical, Inc., reflecting recent share acquisitions and option grants.

A group of reporting persons, including Manchester Management entities and key individuals, have increased their beneficial ownership in Modular Medical, Inc. to over 10% through recent share and warrant acquisitions.

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 9.6% of Modular Medical, Inc.'s common stock, including shares issuable upon exercise of warrants.

683 Capital Management, LLC, along with affiliated entities and individuals, has reported a beneficial ownership stake of 4.67% in Modular Medical, Inc. as of March 31, 2026.

Bard Associates, Inc. has disclosed a beneficial ownership of 102,831 shares, representing 0.1% of the outstanding common stock of Modular Medical, Inc.

AWM Investment Company, Inc. has filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Modular Medical, Inc. common stock.

Pathfinder Asset Management Ltd has disclosed a 6.43% beneficial ownership stake in Modular Medical, Inc., signaling institutional interest.

Solas Capital Management and Frederick Tucker Golden have reported a 6.8% beneficial ownership stake in Modular Medical, Inc., primarily for investment purposes.